Clinical Trials Logo

Meningococcal Infections clinical trials

View clinical trials related to Meningococcal Infections.

Filter by:

NCT ID: NCT00474266 Completed - Clinical trials for Infections, Meningococcal

Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children

Start date: June 5, 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate, in 12-23 month old children, the non-inferiority of the meningococcal vaccine 134612 given with Priorix-Tetra. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

NCT ID: NCT00471081 Completed - Clinical trials for Infections, Meningococcal

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.

Start date: July 5, 2007
Phase: Phase 2
Study type: Interventional

The purpose of the study is to characterize the safety and immunogenicity of 1 dose of GSK134612 vaccine at 12 months of age and of GSK134612 vaccine administered as 2 doses at 9 and 12 months of age.

NCT ID: NCT00465816 Completed - Clinical trials for Infections, Meningococcal

Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612

Start date: April 11, 2007
Phase: Phase 3
Study type: Interventional

This study will demonstrate the non-inferiority of GSK Biologicals' meningococcal vaccine 134612 when given in an experimental co-administration versus vaccine 134612 alone and versus the experimental co-administration alone in healthy subjects aged 11 through 17 years. There will be 3 groups in this study.

NCT ID: NCT00464815 Completed - Clinical trials for Infections, Meningococcal

Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects

Start date: May 2, 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate, in 11-17 year old subjects, the non-inferiority of meningococcal vaccine GSK134612 compared to licensed meningococcal vaccine Mencevax™.

NCT ID: NCT00454909 Completed - Clinical trials for Infections, Meningococcal

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.

Start date: April 23, 2007
Phase: Phase 2
Study type: Interventional

The purpose of the study is to characterize the safety and immunogenicity of 1 dose of GSK Biologicals' meningococcal vaccine GSK134612 as compared to Menactra® in adolescents/adults 11-25 years of age. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007. The protocol posting has been updated following a protocol amendment.

NCT ID: NCT00453986 Completed - Clinical trials for Infections, Meningococcal

Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults

Start date: April 9, 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate, in 18-55 year old adults, the consistency of different manufactured lots of meningococcal vaccine GSK134612, the non-inferiority of GSK134612 compared to licensed meningococcal vaccine Mencevax™, the non-inferiority of GSK134612 when given in an experimental co-administration with Fluarix™ compared to GSK134612 given alone and the immunogenicity of GSK134612 given with Fluarix™. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

NCT ID: NCT00450632 Completed - Clinical trials for Meningococcal Infections

Creation of a Biotheque of Patients of Seine-Maritime With Meningococcal Infection

Start date: September 2005
Phase: N/A
Study type: Observational

The main objective of this study is to constitute a biotheque of patients with meningococcal disease to enable results to be interpreted and genetic factors to be determined

NCT ID: NCT00450437 Completed - Clinical trials for Meningococcal Meningitis

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults

Start date: March 2007
Phase: Phase 3
Study type: Interventional

This study will evaluate the lot to lot consistency, safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine in healthy US adolescents and adults.

NCT ID: NCT00444951 Completed - Clinical trials for Meningococcal Infections

Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia

Start date: February 2007
Phase: Phase 3
Study type: Interventional

This study will be conducted among adolescents in Saudi Arabia who previously received one dose of A, C, Y, W 135 and at least one dose of A, C meningococcal polysaccharide vaccine. This study will evaluate the booster administration of Menactra® (Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine) compared with Mencevax® (Meningococcal A, C, Y, and W 135 Polysaccharide vaccine)in terms of their serum bactericidal antibody responses.

NCT ID: NCT00433914 Completed - Clinical trials for Meningococcal Disease

Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants

Start date: February 2007
Phase: Phase 2
Study type: Interventional

To explore safety, Tolerability and immunogenicity of two formulations of a Meningococcal B Recombinant Vaccine when administered to healthy infants.